Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
American Journal of Physiology. Renal Physiology|February 10, 2017
Calcium channel blockade blunts the renal effects of acute nitric oxide synthase inhibition in healthy humansAlberto Montanari, Davide Lazzeroni, Giovanna Pelà, et al.
Diabetes|April 15, 2017
Renal and Vascular Effects of Uric Acid Lowering in Normouricemic Patients With Uncomplicated Type 1 DiabetesYuliya Lytvyn, Ronnie Har, Amy Locke, et al.
Diabetes Research and Clinical Practice|July 3, 2024
Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetesLuxcia Kugathasan, Vikas S Sridhar, Yuliya Lytvyn, et al.
International Journal of Dermatology|February 7, 2022
Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic reviewJustin D Lu, Yuliya Lytvyn, Asfandyar Mufti, et al.
Transplantation|August 12, 2021
Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical TrialsVikas S Sridhar, Jaya Prakash N Ambinathan, Pieter Gillard, et al.
BMC Rheumatology|October 2, 2025
Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic reviewAaron Teel, Adrian Grebowicz, Yuliya Lytvyn, et al.
Circulation|July 21, 2022
Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme InhibitionYuliya Lytvyn, Karen Kimura, Nuala Peter, et al.
Diabetologia|December 23, 2016
Assessment of urinary microparticles in normotensive patients with type 1 diabetesYuliya Lytvyn, Fengxia Xiao, Christopher R J Kennedy, et al.
Archives of Dermatological Research|May 22, 2024
Signatures of epigenetic, biological and mitotic age acceleration and telomere shortening are associated with arsenic-induced skin lesionsRichie Jeremian, Yuliya Lytvyn, Rayyan Fotovati, et al.
Diabetes, Obesity & Metabolism|March 8, 2019
Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?Rosalie A Scholtes, Michaël J B van Baar, Yuliya Lytvyn, et al.
Pageof 8